CAJ | 학술논문

目的：：观察经皮冠脉介入法( percutaneous coronary intervention,PCI)围术期替格瑞洛联合替罗非班抗血小板出血风险。方法：回顾性分析我院急性冠脉综合征并成功完成PCI手术的患者328例,其中替格瑞洛组172例,氢氯吡格雷组156例,所有患者均在术后给予替罗非班11.5 h,并长期口服阿司匹林100 mg,1次/d。分析患者临床资料观察PCI术后30 d内出血情况。结果：两组患者间一般情况、危险因素、临床资料、临床用药及PCI 数据等均无统计学意义。替格瑞洛联合替罗非班组和氢氯吡格雷联合替罗非班组,两组均未见致命性出血患者。替格瑞洛组发生非致命性出血发生率为9．30%；氯吡格雷组为7．05%,两组比较差异无统计学意义(χ2=0．157,P>0．05)。结论：与氢氯吡格雷相比,PCI术后替格瑞洛联合替罗非班不会增加患者的出血风险。
목적：：관찰경피관맥개입법( percutaneous coronary intervention,PCI)위술기체격서락연합체라비반항혈소판출혈풍험。방법：회고성분석아원급성관맥종합정병성공완성PCI수술적환자328례,기중체격서락조172례,경록필격뢰조156례,소유환자균재술후급여체라비반11.5 h,병장기구복아사필림100 mg,1차/d。분석환자림상자료관찰PCI술후30 d내출혈정황。결과：량조환자간일반정황、위험인소、림상자료、림상용약급PCI 수거등균무통계학의의。체격서락연합체라비반조화경록필격뢰연합체라비반조,량조균미견치명성출혈환자。체격서락조발생비치명성출혈발생솔위9．30%；록필격뢰조위7．05%,량조비교차이무통계학의의(χ2=0．157,P>0．05)。결론：여경록필격뢰상비,PCI술후체격서락연합체라비반불회증가환자적출혈풍험。
Objective:To observe the bleeding risk in patients treated with ticagrelor and tirofiban during perioperative period of percutaneous coronary intervention. Methods:A retrospective analysis of 328 patients with ACS who accepted PCI therapy in our hos-pital was performed. 172 cases were administrated ticagrelor and 156 cases were given clopidogrel. All patients were administrated tirofi-ban by intravenous transfusion for 11 hours and 30 minutes and aspirin 100 mg per day after PCI. The clinical bleeding data of the pa-tients within 30 days were analyzed. Results:There was no significant difference between two groups in general,risk factors,clinical da-ta,clinical medication and PCI data. No fatal hemorrhage was found in both groups. Non-fatal bleeding in ticagrelor group occurred in 9. 30%,in clopidogrel group 7. 05%,and the difference between the two groups had no statistical significance (P>0. 05). Conclusion:Compared with clopidogrel,ticagrelor combined with tirofiban did not increase the risk of hemorrhage patients after PCI.